APO Research
Talk to an analyst

APO RESEARCH · REPORT

Plasma Products and Derivatives

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Plasma Products and Derivatives Market Analysis and Forecast 2026-2032

2 January 2026209 pages

Choose your research edition.

Industry ResearchPlasma Products and Derivatives Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Plasma Products and Derivatives Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Plasma Products and Derivatives Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Plasma Products and Derivatives Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Plasma Products and Derivatives Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Plasma Products and Derivatives market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Plasma Products and Derivatives is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Plasma Products and Derivatives is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Plasma Products and Derivatives is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Plasma Products and Derivatives is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Plasma Products and Derivatives include Takeda, RAAS, Shuanglin Bio, Hualan Bio, Tiantan Bio, Yuanda Shuyang, Weiguang Bio, Octapharma and Nanyue Bio, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Plasma Products and Derivatives, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Plasma Products and Derivatives, also provides the revenue of main regions and countries. Of the upcoming market potential for Plasma Products and Derivatives, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Plasma Products and Derivatives revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Plasma Products and Derivatives market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Plasma Products and Derivatives revenue, projected growth trends, production technology, application and end-user industry.

Plasma Products and Derivatives Segment by Company

Takeda

RAAS

Shuanglin Bio

Hualan Bio

Tiantan Bio

Yuanda Shuyang

Weiguang Bio

Octapharma

Nanyue Bio

LFB Group

KM Biologics

Kedrion

Grifols

CSL

CBPO

BPL

Boya Bio

Biotest

Plasma Products and Derivatives Segment by Type

Albumin

Immune Globulin

Coagulation Factor

Others

Plasma Products and Derivatives Segment by Application

Hospital

Retail Pharmacy

Others

Plasma Products and Derivatives Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Products and Derivatives market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Plasma Products and Derivatives and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Products and Derivatives.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Plasma Products and Derivatives in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Plasma Products and Derivatives company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Plasma Products and Derivatives revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Plasma Products and Derivatives Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Albumin Major Player Table 3. Immune Globulin Major Player Table 4. Coagulation Factor Major Player Table 5. Others Major Player Table 6. Global Plasma Products and Derivatives Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Retail Pharmacy Major Player Table 9. Others Major Player Table 10. Plasma Products and Derivatives Industry Trends Table 11. Plasma Products and Derivatives Industry Drivers Table 12. Plasma Products and Derivatives Industry Opportunities and Challenges Table 13. Plasma Products and Derivatives Industry Restraints Table 14. Global Plasma Products and Derivatives Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Plasma Products and Derivatives Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Plasma Products and Derivatives Market Share by Region (2021-2026) Table 17. Global Plasma Products and Derivatives Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Plasma Products and Derivatives Market Share by Region (2027-2032) Table 19. Global Plasma Products and Derivatives Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Plasma Products and Derivatives Revenue Market Share by Players (2021-2026) Table 21. Global Plasma Products and Derivatives Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Plasma Products and Derivatives Key Players Headquarters & Area Served Table 23. Global Plasma Products and Derivatives Players, Product Type & Application Table 24. Global Plasma Products and Derivatives Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Plasma Products and Derivatives by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Plasma Products and Derivatives Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Plasma Products and Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Plasma Products and Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Plasma Products and Derivatives Revenue Market Share by Type (2021-2026) Table 31. Global Plasma Products and Derivatives Revenue Market Share by Type (2027-2032) Table 32. Global Plasma Products and Derivatives Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Plasma Products and Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Plasma Products and Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Plasma Products and Derivatives Revenue Market Share by Application (2021-2026) Table 36. Global Plasma Products and Derivatives Revenue Market Share by Application (2027-2032) Table 37. Takeda Company Information Table 38. Takeda Business Overview Table 39. Takeda Plasma Products and Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Takeda Plasma Products and Derivatives Product Portfolio Table 41. Takeda Recent Development Table 42. RAAS Company Information Table 43. RAAS Business Overview Table 44. RAAS Plasma Products and Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. RAAS Plasma Products and Derivatives Product Portfolio Table 46. RAAS Recent Development Table 47. Shuanglin Bio Company Information Table 48. Shuanglin Bio Business Overview Table 49. Shuanglin Bio Plasma Products and Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Shuanglin Bio Plasma Products and Derivatives Product Portfolio Table 51. Shuanglin Bio Recent Development Table 52. Hualan Bio Company Information Table 53. Hualan Bio Business Overview Table 54. Hualan Bio Plasma Products and Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Hualan Bio Plasma Products and Derivatives Product Portfolio Table 56. Hualan Bio Recent Development Table 57. Tiantan Bio Company Information Table 58. Tiantan Bio Business Overview Table 59. Tiantan Bio Plasma Products and Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Tiantan Bio Plasma Products and Derivatives Product Portfolio Table 61. Tiantan Bio Recent Development Table 62. Yuanda Shuyang Company Information Table 63. Yuanda Shuyang Business Overview Table 64. Yuanda Shuyang Plasma Products and Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Yuanda Shuyang Plasma Products and Derivatives Product Portfolio Table 66. Yuanda Shuyang Recent Development Table 67. Weiguang Bio Company Information Table 68. Weiguang Bio Business Overview Table 69. Weiguang Bio Plasma Products and Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Weiguang Bio Plasma Products and Derivatives Product Portfolio Table 71. Weiguang Bio Recent Development Table 72. Octapharma Company Information Table 73. Octapharma Business Overview Table 74. Octapharma Plasma Products and Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Octapharma Plasma Products and Derivatives Product Portfolio Table 76. Octapharma Recent Development Table 77. Nanyue Bio Company Information Table 78. Nanyue Bio Business Overview Table 79. Nanyue Bio Plasma Products and Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Nanyue Bio Plasma Products and Derivatives Product Portfolio Table 81. Nanyue Bio Recent Development Table 82. LFB Group Company Information Table 83. LFB Group Business Overview Table 84. LFB Group Plasma Products and Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. LFB Group Plasma Products and Derivatives Product Portfolio Table 86. LFB Group Recent Development Table 87. KM Biologics Company Information Table 88. KM Biologics Business Overview Table 89. KM Biologics Plasma Products and Derivatives Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. KM Biologics Plasma Products and Derivatives Product Portfolio Table 91. KM Biologics Recent Development Table 92. Kedrion Company Information Table 93. Kedrion Business Overview Table 94. Kedrion Plasma Products and Derivatives Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Kedrion Plasma Products and Derivatives Product Portfolio Table 96. Kedrion Recent Development Table 97. Grifols Company Information Table 98. Grifols Business Overview Table 99. Grifols Plasma Products and Derivatives Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Grifols Plasma Products and Derivatives Product Portfolio Table 101. Grifols Recent Development Table 102. CSL Company Information Table 103. CSL Business Overview Table 104. CSL Plasma Products and Derivatives Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. CSL Plasma Products and Derivatives Product Portfolio Table 106. CSL Recent Development Table 107. CBPO Company Information Table 108. CBPO Business Overview Table 109. CBPO Plasma Products and Derivatives Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. CBPO Plasma Products and Derivatives Product Portfolio Table 111. CBPO Recent Development Table 112. BPL Company Information Table 113. BPL Business Overview Table 114. BPL Plasma Products and Derivatives Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. BPL Plasma Products and Derivatives Product Portfolio Table 116. BPL Recent Development Table 117. Boya Bio Company Information Table 118. Boya Bio Business Overview Table 119. Boya Bio Plasma Products and Derivatives Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Boya Bio Plasma Products and Derivatives Product Portfolio Table 121. Boya Bio Recent Development Table 122. Biotest Company Information Table 123. Biotest Business Overview Table 124. Biotest Plasma Products and Derivatives Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Biotest Plasma Products and Derivatives Product Portfolio Table 126. Biotest Recent Development Table 127. North America Plasma Products and Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Plasma Products and Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Plasma Products and Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 130. North America Plasma Products and Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 131. North America Plasma Products and Derivatives Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Plasma Products and Derivatives Revenue by Country (2021-2026) & (US$ Million) Table 133. North America Plasma Products and Derivatives Revenue by Country (US$ Million) & (2027-2032) Table 134. Europe Plasma Products and Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 135. Europe Plasma Products and Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 136. Europe Plasma Products and Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Plasma Products and Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Plasma Products and Derivatives Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Europe Plasma Products and Derivatives Revenue by Country (2021-2026) & (US$ Million) Table 140. Europe Plasma Products and Derivatives Revenue by Country (US$ Million) & (2027-2032) Table 141. China Plasma Products and Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 142. China Plasma Products and Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 143. China Plasma Products and Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 144. China Plasma Products and Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia Plasma Products and Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 146. Asia Plasma Products and Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 147. Asia Plasma Products and Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 148. Asia Plasma Products and Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 149. Asia Plasma Products and Derivatives Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Asia Plasma Products and Derivatives Revenue by Region (US$ Million) & (2021-2026) Table 151. Asia Plasma Products and Derivatives Revenue by Region (US$ Million) & (2027-2032) Table 152. SAMEA Plasma Products and Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 153. SAMEA Plasma Products and Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 154. SAMEA Plasma Products and Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 155. SAMEA Plasma Products and Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 156. SAMEA Plasma Products and Derivatives Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. SAMEA Plasma Products and Derivatives Revenue by Country (2021-2026) & (US$ Million) Table 158. SAMEA Plasma Products and Derivatives Revenue by Country (US$ Million) & (2027-2032) Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Plasma Products and Derivatives Image Figure 2. Global Plasma Products and Derivatives Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Plasma Products and Derivatives Market Size Share 2021 VS 2025 VS 2032 Figure 4. Albumin Image Figure 5. Immune Globulin Image Figure 6. Coagulation Factor Image Figure 7. Others Image Figure 8. Global Plasma Products and Derivatives Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Plasma Products and Derivatives Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Retail Pharmacy Image Figure 12. Others Image Figure 13. Global Plasma Products and Derivatives Market Size (US$ Million) & (2021-2032) Figure 14. Global Plasma Products and Derivatives Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Plasma Products and Derivatives Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Plasma Products and Derivatives Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Plasma Products and Derivatives Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Plasma Products and Derivatives Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Plasma Products and Derivatives Revenue Market Share by Type (2021-2032) Figure 21. Global Plasma Products and Derivatives Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Plasma Products and Derivatives Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Plasma Products and Derivatives Revenue Market Share by Application (2021-2032) Figure 24. North America Plasma Products and Derivatives Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Plasma Products and Derivatives Revenue Share by Type (2021-2032) Figure 26. North America Plasma Products and Derivatives Revenue Share by Application (2021-2032) Figure 27. North America Plasma Products and Derivatives Revenue Share by Country (2021-2032) Figure 28. United States Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Plasma Products and Derivatives Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Plasma Products and Derivatives Revenue Share by Type (2021-2032) Figure 33. Europe Plasma Products and Derivatives Revenue Share by Application (2021-2032) Figure 34. Europe Plasma Products and Derivatives Revenue Share by Country (2021-2032) Figure 35. Germany Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Plasma Products and Derivatives Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Plasma Products and Derivatives Revenue Share by Type (2021-2032) Figure 45. China Plasma Products and Derivatives Revenue Share by Application (2021-2032) Figure 46. Asia Plasma Products and Derivatives Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Plasma Products and Derivatives Revenue Share by Type (2021-2032) Figure 48. Asia Plasma Products and Derivatives Revenue Share by Application (2021-2032) Figure 49. Asia Plasma Products and Derivatives Revenue Share by Region (2021-2032) Figure 50. Japan Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Plasma Products and Derivatives Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Plasma Products and Derivatives Revenue Share by Type (2021-2032) Figure 58. SAMEA Plasma Products and Derivatives Revenue Share by Application (2021-2032) Figure 59. SAMEA Plasma Products and Derivatives Revenue Share by Country (2021-2032) Figure 60. Brazil Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Plasma Products and Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Albumin
  • Immune Globulin
  • Coagulation Factor
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Others
Companies covered
  • Takeda
  • RAAS
  • Shuanglin Bio
  • Hualan Bio
  • Tiantan Bio
  • Yuanda Shuyang
  • Weiguang Bio
  • Octapharma
  • Nanyue Bio
  • LFB Group
  • KM Biologics
  • Kedrion
  • Grifols
  • CSL
  • CBPO
  • BPL
  • Boya Bio
  • Biotest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Plasma Products and Derivatives Market by Type
  3. 1.2.1 Global Plasma Products and Derivatives Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Albumin
  5. 1.2.3 Immune Globulin
  6. 1.2.4 Coagulation Factor
  7. 1.2.5 Others
  8. 1.3 Plasma Products and Derivatives Market by Application
  9. 1.3.1 Global Plasma Products and Derivatives Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Retail Pharmacy
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Plasma Products and Derivatives Market Dynamics
  1. 2.1 Plasma Products and Derivatives Industry Trends
  2. 2.2 Plasma Products and Derivatives Industry Drivers
  3. 2.3 Plasma Products and Derivatives Industry Opportunities and Challenges
  4. 2.4 Plasma Products and Derivatives Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Plasma Products and Derivatives Market Perspective (2021-2032)
  2. 3.2 Global Plasma Products and Derivatives Growth Trends by Region
  3. 3.2.1 Global Plasma Products and Derivatives Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Plasma Products and Derivatives Market Size by Region (2021-2026)
  5. 3.2.3 Global Plasma Products and Derivatives Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Plasma Products and Derivatives Revenue by Players
  2. 4.1.1 Global Plasma Products and Derivatives Revenue by Players (2021-2026)
  3. 4.1.2 Global Plasma Products and Derivatives Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Plasma Products and Derivatives Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Plasma Products and Derivatives Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Plasma Products and Derivatives Key Players Headquarters & Area Served
  7. 4.4 Global Plasma Products and Derivatives Players, Product Type & Application
  8. 4.5 Global Plasma Products and Derivatives Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Plasma Products and Derivatives Market CR5 and HHI
  11. 4.6.3 2025 Plasma Products and Derivatives Tier 1, Tier 2, and Tier 3
5 Plasma Products and Derivatives Market Size by Type
  1. 5.1 Global Plasma Products and Derivatives Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Plasma Products and Derivatives Revenue by Type (2021-2032)
  3. 5.3 Global Plasma Products and Derivatives Revenue Market Share by Type (2021-2032)
6 Plasma Products and Derivatives Market Size by Application
  1. 6.1 Global Plasma Products and Derivatives Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Plasma Products and Derivatives Revenue by Application (2021-2032)
  3. 6.3 Global Plasma Products and Derivatives Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Plasma Products and Derivatives Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 RAAS
  8. 7.2.1 RAAS Company Information
  9. 7.2.2 RAAS Business Overview
  10. 7.2.3 RAAS Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  11. 7.2.4 RAAS Plasma Products and Derivatives Product Portfolio
  12. 7.2.5 RAAS Recent Developments
  13. 7.3 Shuanglin Bio
  14. 7.3.1 Shuanglin Bio Company Information
  15. 7.3.2 Shuanglin Bio Business Overview
  16. 7.3.3 Shuanglin Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Shuanglin Bio Plasma Products and Derivatives Product Portfolio
  18. 7.3.5 Shuanglin Bio Recent Developments
  19. 7.4 Hualan Bio
  20. 7.4.1 Hualan Bio Company Information
  21. 7.4.2 Hualan Bio Business Overview
  22. 7.4.3 Hualan Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Hualan Bio Plasma Products and Derivatives Product Portfolio
  24. 7.4.5 Hualan Bio Recent Developments
  25. 7.5 Tiantan Bio
  26. 7.5.1 Tiantan Bio Company Information
  27. 7.5.2 Tiantan Bio Business Overview
  28. 7.5.3 Tiantan Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Tiantan Bio Plasma Products and Derivatives Product Portfolio
  30. 7.5.5 Tiantan Bio Recent Developments
  31. 7.6 Yuanda Shuyang
  32. 7.6.1 Yuanda Shuyang Company Information
  33. 7.6.2 Yuanda Shuyang Business Overview
  34. 7.6.3 Yuanda Shuyang Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Yuanda Shuyang Plasma Products and Derivatives Product Portfolio
  36. 7.6.5 Yuanda Shuyang Recent Developments
  37. 7.7 Weiguang Bio
  38. 7.7.1 Weiguang Bio Company Information
  39. 7.7.2 Weiguang Bio Business Overview
  40. 7.7.3 Weiguang Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Weiguang Bio Plasma Products and Derivatives Product Portfolio
  42. 7.7.5 Weiguang Bio Recent Developments
  43. 7.8 Octapharma
  44. 7.8.1 Octapharma Company Information
  45. 7.8.2 Octapharma Business Overview
  46. 7.8.3 Octapharma Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Octapharma Plasma Products and Derivatives Product Portfolio
  48. 7.8.5 Octapharma Recent Developments
  49. 7.9 Nanyue Bio
  50. 7.9.1 Nanyue Bio Company Information
  51. 7.9.2 Nanyue Bio Business Overview
  52. 7.9.3 Nanyue Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Nanyue Bio Plasma Products and Derivatives Product Portfolio
  54. 7.9.5 Nanyue Bio Recent Developments
  55. 7.10 LFB Group
  56. 7.10.1 LFB Group Company Information
  57. 7.10.2 LFB Group Business Overview
  58. 7.10.3 LFB Group Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  59. 7.10.4 LFB Group Plasma Products and Derivatives Product Portfolio
  60. 7.10.5 LFB Group Recent Developments
  61. 7.11 KM Biologics
  62. 7.11.1 KM Biologics Company Information
  63. 7.11.2 KM Biologics Business Overview
  64. 7.11.3 KM Biologics Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  65. 7.11.4 KM Biologics Plasma Products and Derivatives Product Portfolio
  66. 7.11.5 KM Biologics Recent Developments
  67. 7.12 Kedrion
  68. 7.12.1 Kedrion Company Information
  69. 7.12.2 Kedrion Business Overview
  70. 7.12.3 Kedrion Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Kedrion Plasma Products and Derivatives Product Portfolio
  72. 7.12.5 Kedrion Recent Developments
  73. 7.13 Grifols
  74. 7.13.1 Grifols Company Information
  75. 7.13.2 Grifols Business Overview
  76. 7.13.3 Grifols Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Grifols Plasma Products and Derivatives Product Portfolio
  78. 7.13.5 Grifols Recent Developments
  79. 7.14 CSL
  80. 7.14.1 CSL Company Information
  81. 7.14.2 CSL Business Overview
  82. 7.14.3 CSL Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  83. 7.14.4 CSL Plasma Products and Derivatives Product Portfolio
  84. 7.14.5 CSL Recent Developments
  85. 7.15 CBPO
  86. 7.15.1 CBPO Company Information
  87. 7.15.2 CBPO Business Overview
  88. 7.15.3 CBPO Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  89. 7.15.4 CBPO Plasma Products and Derivatives Product Portfolio
  90. 7.15.5 CBPO Recent Developments
  91. 7.16 BPL
  92. 7.16.1 BPL Company Information
  93. 7.16.2 BPL Business Overview
  94. 7.16.3 BPL Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  95. 7.16.4 BPL Plasma Products and Derivatives Product Portfolio
  96. 7.16.5 BPL Recent Developments
  97. 7.17 Boya Bio
  98. 7.17.1 Boya Bio Company Information
  99. 7.17.2 Boya Bio Business Overview
  100. 7.17.3 Boya Bio Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Boya Bio Plasma Products and Derivatives Product Portfolio
  102. 7.17.5 Boya Bio Recent Developments
  103. 7.18 Biotest
  104. 7.18.1 Biotest Company Information
  105. 7.18.2 Biotest Business Overview
  106. 7.18.3 Biotest Plasma Products and Derivatives Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Biotest Plasma Products and Derivatives Product Portfolio
  108. 7.18.5 Biotest Recent Developments
8 North America
  1. 8.1 North America Plasma Products and Derivatives Revenue (2021-2032)
  2. 8.2 North America Plasma Products and Derivatives Revenue by Type (2021-2032)
  3. 8.2.1 North America Plasma Products and Derivatives Revenue by Type (2021-2026)
  4. 8.2.2 North America Plasma Products and Derivatives Revenue by Type (2027-2032)
  5. 8.3 North America Plasma Products and Derivatives Revenue Share by Type (2021-2032)
  6. 8.4 North America Plasma Products and Derivatives Revenue by Application (2021-2032)
  7. 8.4.1 North America Plasma Products and Derivatives Revenue by Application (2021-2026)
  8. 8.4.2 North America Plasma Products and Derivatives Revenue by Application (2027-2032)
  9. 8.5 North America Plasma Products and Derivatives Revenue Share by Application (2021-2032)
  10. 8.6 North America Plasma Products and Derivatives Revenue by Country
  11. 8.6.1 North America Plasma Products and Derivatives Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Plasma Products and Derivatives Revenue by Country (2021-2026)
  13. 8.6.3 North America Plasma Products and Derivatives Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Plasma Products and Derivatives Revenue (2021-2032)
  2. 9.2 Europe Plasma Products and Derivatives Revenue by Type (2021-2032)
  3. 9.2.1 Europe Plasma Products and Derivatives Revenue by Type (2021-2026)
  4. 9.2.2 Europe Plasma Products and Derivatives Revenue by Type (2027-2032)
  5. 9.3 Europe Plasma Products and Derivatives Revenue Share by Type (2021-2032)
  6. 9.4 Europe Plasma Products and Derivatives Revenue by Application (2021-2032)
  7. 9.4.1 Europe Plasma Products and Derivatives Revenue by Application (2021-2026)
  8. 9.4.2 Europe Plasma Products and Derivatives Revenue by Application (2027-2032)
  9. 9.5 Europe Plasma Products and Derivatives Revenue Share by Application (2021-2032)
  10. 9.6 Europe Plasma Products and Derivatives Revenue by Country
  11. 9.6.1 Europe Plasma Products and Derivatives Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Plasma Products and Derivatives Revenue by Country (2021-2026)
  13. 9.6.3 Europe Plasma Products and Derivatives Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Plasma Products and Derivatives Revenue (2021-2032)
  2. 10.2 China Plasma Products and Derivatives Revenue by Type (2021-2032)
  3. 10.2.1 China Plasma Products and Derivatives Revenue by Type (2021-2026)
  4. 10.2.2 China Plasma Products and Derivatives Revenue by Type (2027-2032)
  5. 10.3 China Plasma Products and Derivatives Revenue Share by Type (2021-2032)
  6. 10.4 China Plasma Products and Derivatives Revenue by Application (2021-2032)
  7. 10.4.1 China Plasma Products and Derivatives Revenue by Application (2021-2026)
  8. 10.4.2 China Plasma Products and Derivatives Revenue by Application (2027-2032)
  9. 10.5 China Plasma Products and Derivatives Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Plasma Products and Derivatives Revenue (2021-2032)
  2. 11.2 Asia Plasma Products and Derivatives Revenue by Type (2021-2032)
  3. 11.2.1 Asia Plasma Products and Derivatives Revenue by Type (2021-2026)
  4. 11.2.2 Asia Plasma Products and Derivatives Revenue by Type (2027-2032)
  5. 11.3 Asia Plasma Products and Derivatives Revenue Share by Type (2021-2032)
  6. 11.4 Asia Plasma Products and Derivatives Revenue by Application (2021-2032)
  7. 11.4.1 Asia Plasma Products and Derivatives Revenue by Application (2021-2026)
  8. 11.4.2 Asia Plasma Products and Derivatives Revenue by Application (2027-2032)
  9. 11.5 Asia Plasma Products and Derivatives Revenue Share by Application (2021-2032)
  10. 11.6 Asia Plasma Products and Derivatives Revenue by Country
  11. 11.6.1 Asia Plasma Products and Derivatives Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Plasma Products and Derivatives Revenue by Country (2021-2026)
  13. 11.6.3 Asia Plasma Products and Derivatives Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Plasma Products and Derivatives Revenue (2021-2032)
  2. 12.2 SAMEA Plasma Products and Derivatives Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Plasma Products and Derivatives Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Plasma Products and Derivatives Revenue by Type (2027-2032)
  5. 12.3 SAMEA Plasma Products and Derivatives Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Plasma Products and Derivatives Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Plasma Products and Derivatives Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Plasma Products and Derivatives Revenue by Application (2027-2032)
  9. 12.5 SAMEA Plasma Products and Derivatives Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Plasma Products and Derivatives Revenue by Country
  11. 12.6.1 SAMEA Plasma Products and Derivatives Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Plasma Products and Derivatives Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Plasma Products and Derivatives Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst